All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the EHA2021 Virtual Congress, the GvHD Hub spoke with Robert Zeiser, Medical Center - University of Freiburg, Freiburg, DE. We asked, What are the main challenges when evaluating novel agents for GvHD prophylaxis?
What are the main challenges when evaluating novel agents for GvHD prophylaxis?
The main challenge identified by Zeiser is that only a small percentage of patients on prophylaxis treatment develop GvHD, making large trials challenging. In addition, the conditioning regimens used in different institutions vary, making it difficult to compare data from trials.
EHA 2019 | What are the current treatment recommendations for acute GvHD and the promotion of the GvL effect?
Robert Zeiser from the University Medical Center Freiburg, Freiburg, DE, discusses the recommendations for the treatment of acute...
Prof. Robert Zeiser | EBMT 2018 | The role of myeloid recipient-derived cells during GvHD
Professor Robert Zeiser from Freiburg University Medical Center discusses the role of myeloid recipient-derived cells during GvHD
Subscribe to get the best content related to GvHD delivered to your inbox